Pfizer PFE unveils its next round of earnings this Tuesday, October 29. Get prepared with Benzinga's ultimate preview for Pfizer's Q3 earnings.
Earnings and Revenue
Analysts covering Pfizer modeled for quarterly EPS of 62 cents on revenue of $12.26 billion.
In the same quarter last year, Pfizer posted a profit of 78 cents on sales of $13.30 billion. The analyst consensus estimate would represent a 20.51% decrease in the company's earnings. Revenue would be down 7.81% from the same quarter last year. Here's how the Pfizer's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q2 2019 | Q1 2019 | Q4 2018 | Q3 2018 |
EPS Estimate | 0.750 | 0.75 | 0.64 | 0.75 |
EPS Actual | 0.800 | 0.850 | 0.64 | 0.78 |
Stock Performance
Over the last 52-week period, shares are down 15.3%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The average rating by analysts on Pfizer stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
Pfizer is scheduled to hold a conference call at 10:00 a.m. ET and it can be accessed here: https://www.webcaster4.com/Webcast/Page/748/31659
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.